ES2139794T3 - Purificacion de inhibidor de proteinasa alfa-1 usando nuevas condiciones de separacion cromatografica. - Google Patents

Purificacion de inhibidor de proteinasa alfa-1 usando nuevas condiciones de separacion cromatografica.

Info

Publication number
ES2139794T3
ES2139794T3 ES95112630T ES95112630T ES2139794T3 ES 2139794 T3 ES2139794 T3 ES 2139794T3 ES 95112630 T ES95112630 T ES 95112630T ES 95112630 T ES95112630 T ES 95112630T ES 2139794 T3 ES2139794 T3 ES 2139794T3
Authority
ES
Spain
Prior art keywords
alpha
purification
chromatographic separation
proteinase inhibitor
new conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95112630T
Other languages
English (en)
Inventor
Wytold R Lebing
Sharon X Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of ES2139794T3 publication Critical patent/ES2139794T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

UNA CROMATOGRAFIA CATIONICA CON SOLUCIONES CON PH INFERIOR A 60 Y BAJA FUERZA IONICA PUEDE UTILIZARSE PARA PURIFICAR INHIBIDOR DE {AL}-1 PROTEINASA HUMANA ({AL}-1 P) DE FLUIDOS BIOLOGICOS QUE COMPRENDEN PLASMA Y FRACCIONES DE PLASMA. LA CROMATOGRAFIA CATIONICA ES VENTAJOSA POR EL HECHO DE QUE EL {AL}1 P ACTIVO NO SE ENLAZA A LA COLUMNA DE CATIONES BAJO ESTAS CONDICIONES, PERO SI OTRAS PROTEINAS, QUE INCLUYEN {AL}-1 P DESNATURALIZADO Y ALBUMINA. EL EFECTO ES QUE EL {AL}-1 PI FLUYE A TRAVES DE LA COLUMNA DE CROMATOGRAFIA QUE DEJA LAS PROTEINAS DE CONTAMINACION DETRAS. LA RECUPERACION DE {AL}-1 PI ES ALTA Y LA MEJORA DE PUREZA ES IMPRESIONANTE.
ES95112630T 1994-08-24 1995-08-11 Purificacion de inhibidor de proteinasa alfa-1 usando nuevas condiciones de separacion cromatografica. Expired - Lifetime ES2139794T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/295,119 US5610285A (en) 1994-08-24 1994-08-24 Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions

Publications (1)

Publication Number Publication Date
ES2139794T3 true ES2139794T3 (es) 2000-02-16

Family

ID=23136291

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95112630T Expired - Lifetime ES2139794T3 (es) 1994-08-24 1995-08-11 Purificacion de inhibidor de proteinasa alfa-1 usando nuevas condiciones de separacion cromatografica.

Country Status (12)

Country Link
US (1) US5610285A (es)
EP (1) EP0698615B1 (es)
JP (1) JP3770414B2 (es)
KR (1) KR100451266B1 (es)
CN (2) CN100548372C (es)
AT (1) ATE187462T1 (es)
CA (2) CA2156007C (es)
DE (1) DE69513751T2 (es)
DK (1) DK0698615T3 (es)
ES (1) ES2139794T3 (es)
GR (1) GR3032728T3 (es)
PT (1) PT698615E (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6884396A (en) * 1995-09-07 1997-03-27 Ppl Therapeutics (Scotland) Ltd Purification of alpha-1 proteinase inhibitor
SE9600796D0 (sv) * 1996-02-29 1996-02-29 Pharmacia Biotech Ab A method of preparing a liquid mixture
US5616693A (en) * 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
AT407114B (de) * 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
AUPP521298A0 (en) * 1998-08-12 1998-09-03 Life Therapeutics Limited Purification of fibrinogen
US6093804A (en) * 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US20050224355A1 (en) * 1999-12-23 2005-10-13 Brendon Conlan Removal of biological contaminants
AUPP790698A0 (en) * 1998-12-23 1999-01-28 Life Therapeutics Limited Separation of microorganisms
AUPP790898A0 (en) 1998-12-23 1999-01-28 Life Therapeutics Limited Renal dialysis
US7704958B1 (en) 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AUPP971399A0 (en) 1999-04-12 1999-05-06 Life Therapeutics Limited Separation of plasma components
US6462180B1 (en) * 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
US7077942B1 (en) * 1999-12-23 2006-07-18 Gradipore Limited Removal of biological contaminants
AUPQ691400A0 (en) * 2000-04-14 2000-05-11 Life Therapeutics Limited Separation of micromolecules
US6800184B2 (en) 2000-04-18 2004-10-05 Gradipore, Limited Electrophoresis separation and treatment of samples
AUPQ697300A0 (en) * 2000-04-18 2000-05-11 Life Therapeutics Limited Separation apparatus
US6923896B2 (en) * 2000-09-22 2005-08-02 The Texas A&M University System Electrophoresis apparatus and method
DE60142520D1 (de) * 2000-10-06 2010-08-19 Arturus Capital Ltd Multi-port-elektrophorese-trennvorrichtung und entsprechendes verfahren
EP1343809B2 (en) 2000-12-14 2023-03-15 Grifols Therapeutics Inc. Method of preparing alpha-1 proteinase inhibitor
AUPR222300A0 (en) * 2000-12-21 2001-01-25 Life Therapeutics Limited Electrophoresis device and method
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2005027821A2 (en) * 2003-09-22 2005-03-31 Kamada Ltd. Large scale preparation of alpha-1 proteinase inhibitor and use thereof
CN1314447C (zh) * 2004-04-12 2007-05-09 爱华生物科技(香港)有限公司 一种具有抑制蛋白酶作用的药物的制备方法
RU2268736C1 (ru) * 2004-06-17 2006-01-27 Общество с ограниченной ответственностью "БиоГениус" Способ получения альфа-1-антитрипсина и продукт для использования в медицине
CA2654446C (en) * 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
US7807435B2 (en) * 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
US20080124303A1 (en) * 2005-12-12 2008-05-29 Cavit Sciences, Inc Methods and compositions for treatment of viral infections
ES2651268T3 (es) 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
MX2009012786A (es) * 2007-06-01 2009-12-10 Hoffmann La Roche Purificacion de inmunoglobulina.
JP5600061B2 (ja) 2007-08-17 2014-10-01 ツェーエスエル ベーリンク ゲゼルシャフト ミット ベシュレンクテル ハフツング α−１−抗トリプシンおよびアポリポタンパク質Ａ−Ｉを精製する方法
US20110237781A1 (en) * 2008-07-18 2011-09-29 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
KR101104637B1 (ko) * 2010-02-26 2012-01-12 한국철도기술연구원 무개화차의 컨테이너 고정장치
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US9938353B2 (en) 2011-06-24 2018-04-10 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2758065B1 (en) 2011-12-30 2021-06-23 Grifols, S.A. Alpha1-proteinase inhibitor for use in delaying the onset or progression of pulmonary exacerbations
US10478508B2 (en) 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
HK1219964A1 (zh) 2013-03-08 2017-04-21 Genzyme Corporation 治疗性蛋白药物物质的整合连续制造
ES2799153T3 (es) 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
KR20160134687A (ko) 2014-03-21 2016-11-23 에프. 호프만-라 로슈 아게 항체의 생체내 반감기의 시험관내 예측방법
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
AU2019332764B2 (en) 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1189674B (de) * 1963-06-12 1965-03-25 Behringwerke Ag Verfahren zur Isolierung von alpha-Antitrypsin
US4379087A (en) * 1982-06-17 1983-04-05 Cutter Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4752576A (en) * 1984-06-14 1988-06-21 Chiron Corporation Expression of α-1 antitrypsin in yeast
US4656254A (en) * 1985-12-02 1987-04-07 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor and antithrombin III
US4629567A (en) * 1986-03-07 1986-12-16 Smithkline-Rit Alpha-1-antiprotease purification
US4749783A (en) 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
FR2610633B1 (fr) * 1987-02-05 1992-09-18 Lille Transfusion Sanguine Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
US5319072A (en) * 1992-01-10 1994-06-07 Alpha Therapeutic Corporation Human antithrombin-III preparation

Also Published As

Publication number Publication date
CA2156007A1 (en) 1996-02-25
AU700638B2 (en) 1999-01-07
PT698615E (pt) 2000-05-31
KR960007617A (ko) 1996-03-22
CA2692337A1 (en) 1996-02-25
KR100451266B1 (ko) 2004-12-23
AU3011195A (en) 1996-03-07
EP0698615B1 (en) 1999-12-08
EP0698615A1 (en) 1996-02-28
US5610285A (en) 1997-03-11
CN1125231A (zh) 1996-06-26
ATE187462T1 (de) 1999-12-15
DE69513751T2 (de) 2000-04-27
CN1572321A (zh) 2005-02-02
CN100548372C (zh) 2009-10-14
DE69513751D1 (de) 2000-01-13
GR3032728T3 (en) 2000-06-30
CA2156007C (en) 2010-03-09
DK0698615T3 (da) 2000-05-15
HK1072372A1 (zh) 2005-08-26
JPH08176198A (ja) 1996-07-09
CN1161371C (zh) 2004-08-11
JP3770414B2 (ja) 2006-04-26

Similar Documents

Publication Publication Date Title
ES2139794T3 (es) Purificacion de inhibidor de proteinasa alfa-1 usando nuevas condiciones de separacion cromatografica.
BR0211470A (pt) Sistema de reciclagem de gás, e, processo para a purificação e a reciclagem de um gás
DK1075488T3 (da) Proteinoprensning ved ionbytningskromatografi
ES2155477T3 (es) Purificacion cromatografica y procedimiento de separacion de acidos nucleicos.
ES2188665T3 (es) Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
ATE184884T1 (de) Fibrinogenkonzentrate aus blutplasma, verfahren und anlage für ihre herstellung
ATE41354T1 (de) Brillengestell und teile davon.
MX9603988A (es) Separacion y eliminacion de impurezas de los tetrafluoroetanos mediante la utilizacion extractiva.
BR0011033A (pt) Métodos de purificação de dna e dna purificado
IT1262899B (it) Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
MX9302279A (es) Metodo para la produccion del factor viii presenteen el plasma, altamente purificado.
EP0669342B1 (de) Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
ATE432946T1 (de) Abtrennung von fibrinogen von plasmaproteasen
WO2004026891A3 (en) Protein purification
BR9609297A (pt) Processo para aumentar of fluxor sanguineo na retina
ATE309811T1 (de) Analgetikum aus schlangengift
ATE150025T1 (de) Verfahren zur herstellung und reinigung von phospholipidmischungen frei von kontaminierenden unkonventionellen viren
ATE175975T1 (de) Verdrängungschromatographisches verfahren und gereinigtes hämoglobin
PE56396A1 (es) Proceso para purificar el antigeno de superficie de la hepatitis b viral que comprende al peptido pres2
EP0777727A4 (en) CLEANED HERPES SIMPLEX VIRUS PROTEASE AND CLEANING METHODS
PT840746E (pt) Metodo para purificacao de proteinas
ITMI941377A0 (it) Purificazione del propofol
BRPI0417252A (pt) processo de purificação de beta interferon humano
RU98117870A (ru) Способ очистки тромбиноподобных протеаз из змеиного яда
DK0724614T3 (da) Lille glasrør indeholdende en tokomponentklæber, fremgangsmåde til fremstilling heraf samt anvendelse af glasrøret.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 698615

Country of ref document: ES